Press Releases

Debiopharm joins discussions with international health organisations to fight anti-microbial resistance at the 2023 World AMR Congress

One drug for one bug: Debiopharm to discuss the potential of pathogen-specific antibiotics at the 2022 World AMR Congress

Debiopharm International SA Initiates a Clinical Trial Phase II study evaluating afabicin in Bone and Joint Infections

Debiopharm International SA Announces positive Phase 2 Clinical Trial with Debio 1450 in ABSSSI patients

Debiopharm International SA Reaches Important Development Milestones for its Staphylococcus-selective antibiotic Debio 1450

Debiopharm International SA to present the latest findings on Debio 1450 at ECCMID

Debiopharm International SA initiates clinical phase II study evaluating Debio 1450 in Staphylococcal skin infections

FDA Grants Fast Track designation to Debiopharm Group’s antibiotic Debio 1450

Debiopharm Group™ Announces Progress in Phase I Single and Multiple Ascending Dose Study of Debio 1450, its Potent Anti-staphylococcal Agent